|
1
|
Sorafenib in advanced hepatocellular carcinoma.
|
N Engl J Med
|
2008
|
54.30
|
|
2
|
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma.
|
Cancer Res
|
2007
|
5.40
|
|
3
|
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
|
J Hepatol
|
2012
|
3.04
|
|
4
|
The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria.
|
Am J Gastroenterol
|
2009
|
2.47
|
|
5
|
Oncogenic role of miR-483-3p at the IGF2/483 locus.
|
Cancer Res
|
2010
|
2.30
|
|
6
|
MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells.
|
Cancer Res
|
2010
|
2.28
|
|
7
|
The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations.
|
Ultrasound Med Biol
|
2006
|
2.27
|
|
8
|
In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2.
|
J Pathol
|
2012
|
2.27
|
|
9
|
Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis.
|
J Hepatol
|
2013
|
2.23
|
|
10
|
Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
|
Liver Int
|
2014
|
2.23
|
|
11
|
MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.
|
Cancer Res
|
2009
|
2.16
|
|
12
|
Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression.
|
Liver Transpl
|
2005
|
2.04
|
|
13
|
MicroRNA involvement in hepatocellular carcinoma.
|
J Cell Mol Med
|
2008
|
1.99
|
|
14
|
Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population.
|
Ann Surg Oncol
|
2008
|
1.98
|
|
15
|
MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality.
|
Clin Cancer Res
|
2009
|
1.84
|
|
16
|
Characterization of focal liver lesions with contrast-enhanced ultrasound.
|
Ultrasound Med Biol
|
2010
|
1.67
|
|
17
|
Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound.
|
Liver Int
|
2013
|
1.57
|
|
18
|
Liver AL amyloidosis as a possible cause of high liver stiffness values.
|
Eur J Gastroenterol Hepatol
|
2010
|
1.56
|
|
19
|
Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas.
|
Hepatology
|
2011
|
1.50
|
|
20
|
Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation.
|
Transplantation
|
2004
|
1.27
|
|
21
|
Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model.
|
Hepatology
|
2012
|
1.23
|
|
22
|
Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis.
|
Eur Radiol
|
2011
|
1.22
|
|
23
|
Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer.
|
Cancer Res
|
2004
|
1.21
|
|
24
|
Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma.
|
Liver Int
|
2007
|
1.15
|
|
25
|
Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism.
|
J Hepatol
|
2009
|
1.14
|
|
26
|
Hepatocellular carcinoma: epidemiology and clinical aspects.
|
Mol Aspects Med
|
2007
|
1.14
|
|
27
|
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
|
Eur J Cancer
|
2013
|
1.12
|
|
28
|
Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma.
|
J Hepatol
|
2008
|
1.11
|
|
29
|
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
|
Int J Cancer
|
2014
|
1.11
|
|
30
|
Mutated beta-catenin evades a microRNA-dependent regulatory loop.
|
Proc Natl Acad Sci U S A
|
2011
|
1.08
|
|
31
|
Metabolic Syndrome: prevalence and prediction of mortality in elderly individuals.
|
Diabetes Care
|
2006
|
1.06
|
|
32
|
Consensus report of the 4th International Forum for Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid Magnetic Resonance Imaging.
|
Korean J Radiol
|
2011
|
1.04
|
|
33
|
Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma.
|
Dig Liver Dis
|
2013
|
1.02
|
|
34
|
Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma.
|
J Hepatol
|
2013
|
1.00
|
|
35
|
Prediction of significant fibrosis in hepatitis C virus infected liver transplant recipients by artificial neural network analysis of clinical factors.
|
Eur J Gastroenterol Hepatol
|
2006
|
0.98
|
|
36
|
Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography.
|
J Hepatol
|
2004
|
0.97
|
|
37
|
Multigene methylation analysis of gastrointestinal tumors: TPEF emerges as a frequent tumor-specific aberrantly methylated marker that can be detected in peripheral blood.
|
Mol Diagn
|
2003
|
0.96
|
|
38
|
Real time contrast enhanced ultrasonography in detection of liver metastases from gastrointestinal cancer.
|
BMC Cancer
|
2007
|
0.96
|
|
39
|
Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease.
|
Liver Int
|
2014
|
0.96
|
|
40
|
Loss of methylation at chromosome 11p15.5 is common in human adult tumors.
|
Oncogene
|
2002
|
0.95
|
|
41
|
Characterization of liver lesions by real-time contrast-enhanced ultrasonography.
|
Eur J Gastroenterol Hepatol
|
2007
|
0.94
|
|
42
|
CDKN1C/P57 is regulated by the Notch target gene Hes1 and induces senescence in human hepatocellular carcinoma.
|
Am J Pathol
|
2012
|
0.93
|
|
43
|
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation.
|
Liver Transpl
|
2010
|
0.93
|
|
44
|
Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.
|
Eur J Gastroenterol Hepatol
|
2010
|
0.92
|
|
45
|
Treatment of hepatocellular carcinoma in Child-Pugh B patients.
|
Dig Liver Dis
|
2013
|
0.92
|
|
46
|
Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma.
|
Oncotarget
|
2013
|
0.91
|
|
47
|
Notch3 intracellular domain accumulates in HepG2 cell line.
|
Anticancer Res
|
2006
|
0.91
|
|
48
|
GADD45-alpha expression in cirrhosis and hepatocellular carcinoma: relationship with DNA repair and proliferation.
|
Hum Pathol
|
2005
|
0.91
|
|
49
|
Oxidative stress EPR measurement in human liver by radical-probe technique. Correlation with etiology, histology and cell proliferation.
|
Free Radic Res
|
2002
|
0.90
|
|
50
|
Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension?
|
J Vasc Interv Radiol
|
2013
|
0.89
|
|
51
|
The intermediate hepatocellular carcinoma stage: Should treatment be expanded?
|
Dig Liver Dis
|
2010
|
0.88
|
|
52
|
Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study.
|
Oncologist
|
2013
|
0.87
|
|
53
|
Quantification of enhancement of focal liver lesions during contrast-enhanced ultrasound (CEUS). Analysis of ten selected frames is more simple but as reliable as the analysis of the entire loop for most parameters.
|
Eur J Radiol
|
2011
|
0.86
|
|
54
|
Durable complete response of hepatocellular carcinoma after metronomic capecitabine.
|
Tumori
|
2011
|
0.86
|
|
55
|
Conditional survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients.
|
Clin Cancer Res
|
2012
|
0.86
|
|
56
|
Serum albumin-bound proteomic signature for early detection and staging of hepatocarcinoma: sample variability and data classification.
|
Clin Chem Lab Med
|
2010
|
0.85
|
|
57
|
Cost analysis of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma.
|
Dig Liver Dis
|
2010
|
0.85
|
|
58
|
p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma.
|
Mol Cancer Res
|
2013
|
0.84
|
|
59
|
Associations of the -174 G/C interleukin-6 gene promoter polymorphism with serum interleukin 6 and mortality in the elderly.
|
Biogerontology
|
2005
|
0.83
|
|
60
|
Human hepatocellular carcinoma expresses specific PCNA isoforms: an in vivo and in vitro evaluation.
|
Lab Invest
|
2008
|
0.83
|
|
61
|
Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma.
|
Liver Cancer
|
2012
|
0.83
|
|
62
|
Interleukin-1beta and interleukin-6 gene polymorphisms as risk factors for AD: a prospective study.
|
Exp Gerontol
|
2005
|
0.82
|
|
63
|
Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis.
|
J Hepatol
|
2005
|
0.82
|
|
64
|
Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine.
|
J Hepatol
|
2005
|
0.81
|
|
65
|
A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.
|
Liver Transpl
|
2007
|
0.81
|
|
66
|
Extracorporeal detoxification for hepatic failure using molecular adsorbent recirculating system: depurative efficiency and clinical results in a long-term follow-up.
|
Artif Organs
|
2013
|
0.81
|
|
67
|
Enhanced uptake of lactosaminated human albumin by rat hepatocarcinomas: implications for an improved chemotherapy of primary liver tumors.
|
Liver Int
|
2005
|
0.81
|
|
68
|
Metronomic capecitabine in patients with hepatocellular carcinoma unresponsive to or ineligible for sorafenib treatment: report of two cases.
|
Hepat Mon
|
2013
|
0.81
|
|
69
|
Doxorubicin coupled to lactosaminated human albumin: a hepatocellular carcinoma targeted drug.
|
Drug Discov Today
|
2008
|
0.81
|
|
70
|
The ART score is not effective to select patients for transarterial chemoembolization retreatment in an Italian series.
|
Dig Dis
|
2014
|
0.80
|
|
71
|
Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma.
|
Mol Imaging Biol
|
2015
|
0.80
|
|
72
|
Doxorubicin coupled to lactosaminated albumin: effect of heterogeneity in drug load on conjugate disposition and hepatocellular carcinoma uptake in rats.
|
Eur J Pharm Sci
|
2007
|
0.80
|
|
73
|
Onset of bronchiolitis obliterans organizing pneumonia in a liver transplant recipient under peg-interferon and ribavirin treatment.
|
Intern Emerg Med
|
2008
|
0.80
|
|
74
|
Autoimmune Hepatitis and Celiac Disease: Case Report Showing an Entero-Hepatic Link.
|
Case Rep Gastroenterol
|
2010
|
0.80
|
|
75
|
Recent advances in the diagnosis of hepatocellular carcinoma.
|
Hepatol Res
|
2007
|
0.79
|
|
76
|
Medical treatment of hepatocellular carcinoma.
|
Mediterr J Hematol Infect Dis
|
2009
|
0.79
|
|
77
|
In human hepatocellular carcinoma in cirrhosis proliferating cell nuclear antigen (PCNA) is involved in cell proliferation and cooperates with P21 in DNA repair.
|
J Hepatol
|
2003
|
0.79
|
|
78
|
Clinical impact of ultrasound-related techniques on the diagnosis of focal liver lesions.
|
Liver Cancer
|
2012
|
0.79
|
|
79
|
Fibromyalgia and coeliac disease: a media hype or an emerging clinical problem?
|
Clin Exp Rheumatol
|
2013
|
0.79
|
|
80
|
Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma.
|
BMC Cancer
|
2014
|
0.79
|
|
81
|
Relationship between hepatic haemodynamics assessed by Doppler ultrasound and liver stiffness.
|
Dig Liver Dis
|
2011
|
0.78
|
|
82
|
Orthotopic liver transplantation (OLT): Contribution of imaging and interventional radiology in preparing the transplantation and managing complications. Part 2: Post-OLT complications and their treatment.
|
Radiol Med
|
2006
|
0.78
|
|
83
|
A modeling study of bilirubin kinetics during Molecular Adsorbent Recirculating System sessions.
|
Artif Organs
|
2006
|
0.78
|
|
84
|
Outcomes from a program of home care attendance in very frail elderly subjects.
|
Arch Gerontol Geriatr
|
2006
|
0.78
|
|
85
|
TACE performed in patients with a single nodule of hepatocellular carcinoma.
|
BMC Cancer
|
2014
|
0.77
|
|
86
|
The appropriate allocation of CEUS in the diagnostic algorithm of liver lesions: a debated issue.
|
Ultrasound Med Biol
|
2012
|
0.77
|
|
87
|
Contrast enhanced ultrasonography for the evaluation of coil embolization of splenic artery aneurysm.
|
Circulation
|
2010
|
0.77
|
|
88
|
Orthotopic liver transplantation (OLT): Contribution of diagnostic imaging and interventional radiology in preparing the transplantation and managing complications. Part 1: Indications, surgical technique, diagnostic imaging and interventional radiology before transplantation from cadaveric and living donor.
|
Radiol Med
|
2006
|
0.77
|
|
89
|
Liver metastases from rectal carcinoma: disease progression during chemotherapy despite loss of arterial-phase hypervascularity on real-time contrast-enhanced harmonic sonography at low acoustic energy.
|
J Clin Ultrasound
|
2003
|
0.77
|
|
90
|
Effect of Levovist on splanchnic hemodynamics in cirrhotic patients.
|
Ultrasound Med Biol
|
2003
|
0.76
|
|
91
|
A conjugate of doxorubicin with lactosaminated albumin enhances the drug concentrations in all the forms of rat hepatocellular carcinomas independently of their differentiation grade.
|
Liver Int
|
2006
|
0.76
|
|
92
|
A case of intractable pruritus in Turner's syndrome successfully treated with molecular adsorbent recirculating system.
|
Intern Emerg Med
|
2008
|
0.76
|
|
93
|
Recent advances in the imaging of hepatocellular carcinoma. From ultrasound to positron emission tomography scan.
|
Saudi Med J
|
2007
|
0.76
|
|
94
|
Screening tests for hepatocellular carcinoma.
|
Hepatology
|
2003
|
0.75
|
|
95
|
Use of perfusional angiosonography in liver transplantation and conservative management of post-transplant intra-hepatic pseudo-aneurysm.
|
Transpl Int
|
2004
|
0.75
|
|
96
|
Stiffness and amyloidosis: to be continued….
|
Eur J Gastroenterol Hepatol
|
2010
|
0.75
|
|
97
|
Yttrium 90 radioembolization: the horizon is changing for patients with intermediate and advanced hepatocellular carcinoma.
|
Hepatology
|
2013
|
0.75
|
|
98
|
Selecting patients with hepatocellular carcinoma for transplantation.
|
Liver Transpl
|
2007
|
0.75
|
|
99
|
"Survival benefit": the final destination, with still a long way to go.
|
Dig Liver Dis
|
2010
|
0.75
|
|
100
|
Portal pressure and Doppler.
|
Ultrasound Med Biol
|
2003
|
0.75
|
|
101
|
Cholangiocarcinoma in Cirrhosis: Value of Hepatocyte Specific Magnetic Resonance Imaging.
|
Dig Dis
|
2015
|
0.75
|
|
102
|
State of the art: hepatocellular carcinoma.
|
Future Oncol
|
2014
|
0.75
|
|
103
|
Cirrhosis does not shift the circadian phase of plasma fibrinolysis.
|
Am J Gastroenterol
|
2002
|
0.75
|
|
104
|
Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection.
|
Eur J Gastroenterol Hepatol
|
2013
|
0.75
|
|
105
|
[Pitfalls of cardiologic consultation in internal medicine: an obvious case of alcoholic liver cirrhosis].
|
G Ital Cardiol (Rome)
|
2008
|
0.75
|
|
106
|
Eosinophilic granulomatosis with polyangiitis of the major salivary glands: a case of sialadenitis in a young patient.
|
Intern Med
|
2013
|
0.75
|
|
107
|
A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma.
|
Dig Liver Dis
|
2011
|
0.75
|
|
108
|
Caution in the use of boldo in herbal laxatives: a case of hepatotoxicity.
|
Scand J Gastroenterol
|
2005
|
0.75
|
|
109
|
Design, synthesis and biological evaluation of pyrazole derivatives as potential multi-kinase inhibitors in hepatocellular carcinoma.
|
Eur J Med Chem
|
2011
|
0.75
|
|
110
|
Squamous cell carcinoma of the liver: metastasis or primary neoplasm?
|
J Clin Ultrasound
|
2005
|
0.75
|